This month, we explore Medicare genetic testing overpayments, why the new TCET rule likely won’t speed up breakthrough device coverage, and possible Part B payment cuts to physicians.

We cover the economic burden of diagnostic error, the FDA proceeding without Congress on laboratory-developed test reform, and what the latest CFTR screening recommendations mean for labs.

This issue shares how to achieve a successful FDA cGMP inspection through a pre-inspection audit, how to comply with the 60-Day Rule, and ensuring proper documentation for laboratory services.

In our latest report, we cover how new FTC rules could chill healthcare mergers and acquisitions, the top 10 clinical lab acquisitions of 2023, and the latest in COVID-19 testing.